The Cushing syndrome induced by medroxyprogesterone acetate.
Siminoski
K
K
Toronto General Hospital, Ontario, Canada.
Goss
P
P
Drucker
D J
DJ
D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000628:therapy; D003480:Cushing Syndrome / Q000139:chemically induced*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D066298:In Vitro Techniques; D007680:Kidney Neoplasms / Q000628:therapy; D008525:Medroxyprogesterone / Q000009:adverse effects / Q000031:analogs & derivatives*; D017258:Medroxyprogesterone Acetate; D051379:Mice; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism; D011333:Pro-Opiomelanocortin / Q000235:genetics; D012333:RNA, Messenger / Q000187:drug effects
D000970:Antineoplastic Agents; D012333:RNA, Messenger; D011333:Pro-Opiomelanocortin; D000324:Adrenocorticotropic Hormone; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; D006854:Hydrocortisone